ribociclib succinate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
ribociclib succinate: clinical details
Prescribing considerations
- Initiation and supervision require a clinician experienced in anticancer therapy.
- Confirm HR-positive and HER2-negative tumour status using an appropriate validated test.
- Review cardiac history, QT-prolonging factors, electrolytes, hepatic and renal function, concomitant medicines and pulmonary symptoms.
- Safety and efficacy have not been studied in critical visceral disease or established in patients younger than 18 years.
- Discuss pregnancy prevention and potential fertility effects before treatment where relevant.
Contraindications and cautions
- Hypersensitivity to ribociclib, peanut, soya or any listed excipient.
- Avoid use in patients with existing or substantial risk of QT prolongation, including long-QT syndrome, significant uncontrolled cardiac disease or uncorrected electrolyte abnormalities.
- Use particular caution in severe renal impairment because clinical efficacy at the altered exposure has not been established.
Monitoring
- Full blood count before and during treatment, with particular attention to neutropenia and other cytopenias.
- Liver-function tests before and during treatment.
- ECG assessment and serum potassium, calcium, magnesium and phosphate monitoring; correct abnormalities.
- Assess new or worsening respiratory symptoms promptly for interstitial lung disease or pneumonitis.
- If serum creatinine rises, assess renal function by additional methods because ribociclib can inhibit tubular creatinine secretion.
Clinical pharmacology
Ribociclib is an orally bioavailable selective CDK4/6 inhibitor. It is metabolised mainly by CYP3A4 and is itself a clinically important CYP3A4 inhibitor. Its effective plasma half-life supports accumulation with repeated administration, and elimination is predominantly faecal.
Formulation and product differences
- The selected product is an unscored film-coated tablet containing ribociclib succinate.
- Tablets must remain intact and should not be chewed, crushed or split.
- The formulation contains soya lecithin and is unsuitable for people hypersensitive to peanut or soya.
ribociclib succinate interactions
The oncology team and pharmacist should check prescribed, over-the-counter and herbal products before and during treatment.
Strong CYP3A4 inhibitors, including clarithromycin, itraconazole, posaconazole, voriconazole, ritonavir and verapamil
Can substantially increase ribociclib exposure and toxicity; concomitant use should generally be avoided.
Strong CYP3A4 inducers, including rifampicin, carbamazepine, phenytoin and St John’s wort
Can substantially reduce ribociclib exposure and may impair effectiveness; avoid concomitant use.
Medicines that prolong the QT interval, including amiodarone, sotalol, methadone, haloperidol and some antibiotics
May increase the risk of clinically important heart-rhythm disturbance and should generally be avoided.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.